Skip to main content
. 2016 Mar 31;3(3):177–188. doi: 10.1002/ehf2.12088

Figure 3.

Figure 3

Tolvaptan decreased catecholamines and BNP without RAAS enhancement. Changes between baseline and intensive treatment end in catecholamines (A), BNP (B), plasma aldosterone concentration (C), and plasma renin activity (D). **P < 0.01 vs. furosemide. BNP indicates brain natriuretic peptide; PAC, plasma aldosterone concentration; PRA, plasma renin activity; TLV, tolvaptan.